Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
暂无分享,去创建一个
D. Richman | H. Günthard | D. Havlir | C. Spina | J. Wong | C. Ignacio | H F Günthard | J K Wong | D D Richman | D V Havlir | M. Hezareh | M Hezareh | C C Ignacio | C A Spina
[1] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[2] G. Nabel,et al. Activation of HIV gene expression during monocyte differentiation by induction of NF-kB , 1989, Nature.
[3] J S Sinsheimer,et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects , 1996, Journal of virology.
[4] P. Krogstad,et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.
[5] J. Levy,et al. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. , 1989, Immunology.
[6] E A Emini,et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.
[7] D. Richman,et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Chermann,et al. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.
[9] J. Justement,et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[10] F. Cosset,et al. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU , 1996, Journal of virology.
[11] S. Kwok,et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity , 1997, Journal of clinical microbiology.
[12] B. Levine,et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. , 1997, Science.
[13] N. Shen,et al. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.
[14] V. Johnson,et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group , 1993, Antimicrobial Agents and Chemotherapy.
[15] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[16] N. Avdalović,et al. Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. , 1983, Journal of immunological methods.
[17] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[18] J. Levy,et al. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.
[19] D. Richman,et al. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. , 1997, The Journal of clinical investigation.
[20] H. Yoshiyama,et al. Enhancement of HIV replication and giant cell formation by tumor necrosis factor. , 1989, AIDS research and human retroviruses.